The CMS said it will release additional details on participation in early 2026
That result immediately placed retatrutide ahead of every other published GLP-1-class compound at comparable follow-up, including tirzepatide in SURMOUNT-1 at the matched timepoint
E.ZhangQ.AbdulkaderF.BengtssonM.et al (2010)
Among these patients who both take a GLP-1 and have diabetes, the average age is 59.2, and 73.5% are commercially insured
References consulted in writing this blog post: Jaime P Almandoz 1 , Thomas A Wadden 2 , Colleen Tewksbury 3 , Caroline M Apovian 4 , Angela Fitch 5 , Jamy D Ard 6 , Zhaoping Li 7 , Jesse Richards 8 , W Scott Butsch 9 , Irina Jouravskaya 10 , Kadie S Vanderman 11 , Lisa M Neff 10
GLP-1 powerfully slows how quickly your stomach empties food into your intestines, contributing to prolonged fullness